Dasatinib Mechanism: How a Cancer Drug Became a Senolytic
Expert Summary
Dasatinib's senolytic activity was discovered via a bioinformatics screen of senescence survival networks. The key finding: senescent cells upregulate ephrin receptor (EPHA2, EPHB4) signaling, PI3K/AKT, and src-family kinases (YES1, SRC) as survival mechanisms. Dasatinib — as a multi-kinase inhibitor — simultaneously blocks these pathways, triggering apoptosis specifically in senescent cells while leaving non-senescent cells unaffected at senolytic doses.
Key Facts
- Senescence survival network: Senescent cells upregulate anti-apoptotic networks including BCL-2 family proteins AND kinase survival signals (src, ABL, EPHA2). This constitutes their "senescent cell anti-apoptotic pathway" (SCAP). Drugs targeting SCAP components have senolytic activity.
- EPHA2 inhibition: Ephrin receptor A2 (EPHA2) is particularly upregulated in senescent fat progenitor cells (preadipocytes) and epithelial cells. Dasatinib's inhibition of EPHA2 kinase activity removes a key survival signal specific to these senescent cells.
- Src family kinase inhibition: YES1 and SRC kinases are upregulated in senescent cells and contribute to survival by activating AKT and downstream BCL-2 expression. Dasatinib inhibits YES1 and SRC at nanomolar concentrations — far below the concentrations needed for CML treatment.
- BCR-ABL vs senolytic doses: For CML treatment, dasatinib is used at 100 mg daily continuously. For senolytic purposes, the same 100 mg dose is used for only 2–3 days per quarter — a dramatically lower cumulative dose with correspondingly reduced side effect risk.
- Cell type specificity: Dasatinib shows senolytic activity in epithelial cells, preadipocytes, and endothelial cells. It does NOT efficiently clear senescent muscle cells or neurons — where fisetin and quercetin are more active.
- Discovery via transcriptome analysis: The Kirkland lab at Mayo Clinic used network analysis of senescent cell transcriptomes to identify drug candidates. This computational approach was the innovation enabling rapid discovery of dasatinib's senolytic activity.
Recommended Products
Frequently Asked Questions
What makes dasatinib's senolytic activity specific to senescent cells?
Two factors: (1) Senescent cells upregulate the specific kinases dasatinib inhibits (EPHA2, YES1), creating molecular selectivity. (2) The dose used for senolysis (100 mg × 2 days) is the same as for CML treatment, but the intermittent nature means it only acts during the brief window when senolytic plasma levels are maintained.
Could other kinase inhibitors also be senolytic?
Yes. This is an active research area. Navitoclax (ABT-263) is a pure BCL-2/BCL-XL inhibitor with potent senolytic activity. Several other kinase inhibitors are being screened for senolytic activity using the same bioinformatics approach.
Does dasatinib have senolytic activity without quercetin?
Yes, dasatinib alone has documented senolytic activity. However, it preferentially clears certain senescent cell types (epithelial, preadipocytes) while missing others (adipocytes, fibroblasts) that quercetin covers via BCL-2 inhibition. The combination is specifically designed for broad-spectrum senolytic coverage.
Scientific References
- Zhu Y et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015. PMID: 25754370
- Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID: 29988130